4.22

0.94% -0.04

Voyager Therapeutics Inc (VYGR)

Overview News Price History Option Chain Financials Discussions Forecast

Voyager Therapeutics Inc stock is traded at $4.22, with a volume of 275.58K. It is down -0.94% in the last 24 hours and down -19.16% over the past month. Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Previous Close:

$4.26

Open:

$4.29

24h Volume:

275.58K

Relative Volume:

0.66

Market Cap:

$230.52M

Revenue:

$163.78M

Net Income/Loss:

$25.88M

P/E Ratio:

6.4923

EPS:

0.65

Net Cash Flow:

$-28.66M

1W Performance:

-0.24%

1M Performance:

-19.16%

6M Performance:

-38.57%

1Y Performance:

-44.76%

1-Day Range:

$4.205

$4.3537

1-Week Range:

$4.205

$4.53

52-Week Range:

$4.0013

$10.66

Voyager Therapeutics Inc Stock (VYGR) Company Profile

Name

Voyager Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

857-259-5340

Address

75 HAYDEN AVENUE, LEXINGTON, MA

Employee

162

Twitter

@VoyagerTx

Next Earnings Date

2024-11-04

Latest SEC Filings

VYGR's Discussions on Twitter

Compare VYGR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VYGR Voyager Therapeutics Inc	4.22	230.52M	163.78M	25.88M	-28.66M	0.65
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Dec-02-24	Initiated	Citigroup	Buy
Nov-29-24	Resumed	Wedbush	Outperform
Oct-16-24	Initiated	Leerink Partners	Outperform
Mar-26-24	Initiated	Guggenheim	Buy
Mar-19-24	Initiated	H.C. Wainwright	Buy
Mar-07-24	Initiated	Citigroup	Buy
Jan-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight
May-10-23	Initiated	Truist	Buy
Mar-10-23	Initiated	Oppenheimer	Outperform
Oct-07-21	Upgrade	Robert W. Baird	Neutral → Outperform
Feb-26-21	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-03-21	Downgrade	BTIG Research	Buy → Neutral
Feb-03-21	Downgrade	Wedbush	Outperform → Neutral
Dec-24-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-23-20	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-11-20	Downgrade	Oppenheimer	Outperform → Perform
Nov-10-20	Downgrade	Raymond James	Strong Buy → Outperform
Nov-10-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Mar-19-20	Initiated	The Benchmark Company	Buy
Feb-06-20	Initiated	Oppenheimer	Outperform
Nov-15-18	Upgrade	Raymond James	Outperform → Strong Buy
Sep-10-18	Resumed	BTIG Research	Buy
Sep-10-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-04-18	Initiated	H.C. Wainwright	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Mar-12-18	Downgrade	Wedbush	Outperform → Neutral
Feb-02-18	Initiated	Morgan Stanley	Overweight
Nov-28-17	Resumed	Piper Jaffray	Overweight
Oct-31-17	Initiated	Robert W. Baird	Outperform
Oct-27-17	Initiated	Canaccord Genuity	Buy
Oct-23-17	Reiterated	Stifel	Buy
Oct-12-17	Initiated	Raymond James	Outperform
Aug-17-17	Initiated	Evercore ISI	Outperform
Jul-28-17	Resumed	Stifel	Buy

View All

Voyager Therapeutics Inc Stock (VYGR) Latest News

Feb 21, 2025

VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Morningstar

Feb 21, 2025

Levi & Korsinsky Reminds Voyager Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsVYGR - ACCESS Newswire

Feb 21, 2025

Lost Money on Voyager Therapeutics, Inc. (VYGR)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire

Feb 21, 2025

Feb 20, 2025

Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Wednesday - MarketBeat

Feb 20, 2025

Feb 19, 2025

Kirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of Investors - GlobeNewswire

Feb 19, 2025

Kirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of Investors - GlobeNewswire Inc.

Feb 19, 2025

Voyager Therapeutics stock hits 52-week low at $4.12 By Investing.com - Investing.com Nigeria

Feb 19, 2025

Voyager Therapeutics reassesses SOD1-ALS gene therapy program - ALS News Today

Feb 19, 2025

Wedbush Has Bearish Estimate for VYGR FY2025 Earnings - MarketBeat

Feb 19, 2025

Feb 18, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc.VYGR - PR Newswire

Feb 18, 2025

Feb 17, 2025

Voyager Therapeutics (NASDAQ:VYGR) Receives "Outperform" Rating from Wedbush - MarketBeat

Feb 15, 2025

Equities Analysts Issue Forecasts for VYGR FY2025 Earnings - Defense World

Feb 15, 2025

Feb 14, 2025

Voyager Therapeutics COO Robin Swartz sells $30,927 in stock - MSN

Feb 14, 2025

Brokers Issue Forecasts for VYGR FY2029 Earnings - Defense World

Feb 14, 2025

Feb 13, 2025

A company insider recently sold 5,413 shares of Voyager Therapeutics Inc [VYGR]. Should You Sale? - Knox Daily

Feb 13, 2025

Voyager Therapeutics COO Robin Swartz sells $30,927 in stock By Investing.com - Investing.com Australia

Feb 13, 2025

Feb 12, 2025

Voyager Therapeutics' chief legal officer sells $19,393 in stock - MSN

Feb 12, 2025

Voyager Therapeutics CEO Alfred Sandrock sells $74,065 in stock By Investing.com - Investing.com Australia

Feb 12, 2025

Voyager Therapeutics’ chief legal officer sells $19,393 in stock By Investing.com - Investing.com Nigeria

Feb 12, 2025

Voyager Therapeutics stock hits 52-week low at $4.12 - MSN

Feb 12, 2025

Voyager Therapeutics' chief scientific officer sells shares worth $24,087 - MSN

Feb 12, 2025

Voyager Therapeutics’ chief scientific officer sells shares worth $24,087 By Investing.com - Investing.com Nigeria

Feb 12, 2025

Voyager Therapeutics' chief scientific officer sells shares worth $24,087 By Investing.com - Investing.com South Africa

Feb 12, 2025

Voyager Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView

Feb 12, 2025

Voyager Therapeutics' chief legal officer sells $19,393 in stock By Investing.com - Investing.com UK

Feb 12, 2025

Voyager Therapeutics Executives Sell Shares - TradingView

Feb 12, 2025